Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple breath test spot hidden diseases early?

NCT ID NCT07646015

Diagnosis Sponsor: Respyr Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a portable, non-invasive breath analyzer that measures tiny particles in exhaled breath to screen for conditions like type 2 diabetes, liver disease, kidney disease, and lung disease. Researchers will enroll healthy volunteers and people with known diagnoses to build and validate AI algorithms that can identify early signs of metabolic problems. The goal is to create an affordable, easy-to-use screening tool that could help catch diseases before symptoms appear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smart breath analyzer (non-invasive device measuring volatile organic compounds in exhaled breath)
What this could lead to
If validated, this breath analyzer could offer a quick, painless way to screen for multiple metabolic diseases early, enabling timely preventive care.
What could go wrong
This is an early validation study; the device's accuracy and reliability are not yet proven, and AI algorithms may not perform well across diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,000 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers and patients with confirmed metabolic disorders including type 2 diabetes, liver disease, kidney disease, and lung disease recruited from JSS Hospital and Medical College, Mysore, India.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must either be a completely healthy individual as confirmed by blood examination, or a known case of diabetes, kidney disease, liver disease, and lung disease with relevant diagnostic reports tested within 15 days of participation * All genders and ethnicities * Age 18 to 75 years * Participant who has given informed consent * Participant must be fully vaccinated for COVID-19 * Participant must use the smart breath analyzer at fasting condition; if not fasting, minimum gap of 1 hour after water and 3-4 hours after food Exclusion Criteria: * Individual less than 18 or above 75 years of age * Pregnant and lactating females * Known case of ongoing illness such as Cancer, AIDS, COVID-19, Cough, Fever, TB, Chickenpox, Influenza, Mumps, or Tonsillitis * Individual who has not given informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney disorder liver disorder lung disorder metabolic disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Healthy volunteers Kidney diseases Liver diseases Lung diseases Metabolic diseases

Contacts and locations

Locations

  • Dept. of Community Medicine, JSS Medical College

    Mysore, Karnataka, 570015, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.